Your browser doesn't support javascript.
loading
A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena.
Bain, Stephen C; Min, Thinzar.
Affiliation
  • Bain SC; Swansea Bay University Health Board and Swansea University Medical School, Swansea SA2 8PP, UK. Electronic address: s.c.bain@swansea.ac.uk.
  • Min T; Swansea Bay University Health Board and Swansea University Medical School, Swansea SA2 8PP, UK.
Lancet ; 402(10401): 504-505, 2023 08 12.
Article in En | MEDLINE | ID: mdl-37385276
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Incretins Limits: Humans Language: En Journal: Lancet Year: 2023 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Diabetes Mellitus, Type 2 / Incretins Limits: Humans Language: En Journal: Lancet Year: 2023 Document type: Article